Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 5, Pages e003486
Publisher
BMJ
Online
2022-05-24
DOI
10.1136/jitc-2021-003486
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- (2021) Dan Liu et al. Journal for ImmunoTherapy of Cancer
- Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
- (2021) Giandomenico Turchiano et al. Cell Stem Cell
- Preclinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T cells for the Treatment of Acute Myeloid Leukemia
- (2021) Eben I Lichtman et al. CLINICAL CANCER RESEARCH
- Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity
- (2021) Stefan Kiesgen et al. Nature Protocols
- Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
- (2021) Dristhi Ragoonanan et al. Nature Reviews Clinical Oncology
- Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells
- (2021) Kenneth Paul Micklethwaite et al. BLOOD
- Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
- (2021) Bruno L. Cadilha et al. Science Advances
- CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1
- (2021) Chahrazade Kantari-Mimoun et al. Cancer Immunology Research
- Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones
- (2020) Frederic D. Bushman MOLECULAR THERAPY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Calreticulin Blockade Attenuates Murine Acute Lung Injury by Inducing Polarization of M2 Subtype Macrophages
- (2020) Zhilong Jiang et al. Frontiers in Immunology
- Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
- (2020) Yuying Liu et al. Science Immunology
- Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
- (2020) Jennifer M. Logue et al. HAEMATOLOGICA
- Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR
- (2020) Dana Stenger et al. BLOOD
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Organoid Models of Tumor Immunology
- (2020) Kanako Yuki et al. TRENDS IN IMMUNOLOGY
- Biomarkers in individualized management of chimeric antigen receptor T cell therapy
- (2020) Mengyi Du et al. Biomarker Research
- Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
- (2020) Tania Jain et al. Blood Advances
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
- (2020) Kevin R. Parker et al. CELL
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
- (2020) Qing Deng et al. NATURE MEDICINE
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
- (2020) Xiang Zhou et al. Frontiers in Immunology
- Allogeneic CAR T cell therapies for leukemia - R1
- (2019) Waseem Qasim AMERICAN JOURNAL OF HEMATOLOGY
- Developing allogeneic double negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer
- (2019) Jong Bok Lee et al. CLINICAL CANCER RESEARCH
- Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
- (2019) Hongwei Du et al. CANCER CELL
- Early and late hematologic toxicity following CD19 CAR-T cells
- (2019) Shalev Fried et al. BONE MARROW TRANSPLANTATION
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases
- (2019) Daesik Kim et al. Annual Review of Biochemistry
- Toxicities of CD19 CAR-T cell immunotherapy
- (2019) Alexandre V. Hirayama et al. AMERICAN JOURNAL OF HEMATOLOGY
- CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
- (2019) Jonathan P. Mochel et al. AAPS Journal
- 3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids
- (2019) Theresa E Schnalzger et al. EMBO JOURNAL
- CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration
- (2019) Christopher L. Nobles et al. JOURNAL OF CLINICAL INVESTIGATION
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
- (2019) Noelle V. Frey et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening
- (2019) Jim Freeth et al. SLAS Discovery
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL
- (2018) John Rossi et al. BLOOD
- Preclinical Models in Chimeric Antigen Receptor–Engineered T-Cell Therapy
- (2018) Elizabeth Louise Siegler et al. HUMAN GENE THERAPY
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
- (2018) Nicla Porciello et al. Nature Communications
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- (2018) Agne Taraseviciute et al. Cancer Discovery
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
- (2018) Verena Staedtke et al. NATURE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
- (2017) Arnab Ghosh et al. NATURE MEDICINE
- Mapping the genomic landscape of CRISPR–Cas9 cleavage
- (2017) Peter Cameron et al. NATURE METHODS
- CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets
- (2017) Shengdar Q Tsai et al. NATURE METHODS
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- The Human Cell Atlas
- (2017) Aviv Regev et al. eLife
- High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
- (2017) Sarah A. Richman et al. Cancer Immunology Research
- Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?
- (2016) R. Zeiser et al. BLOOD
- Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
- (2016) Annette Künkele et al. CLINICAL CANCER RESEARCH
- Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
- (2016) Paulina J. Paszkiewicz et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated Mice
- (2016) Marie-Louise Sentman et al. JOURNAL OF IMMUNOLOGY
- Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes
- (2016) Sheng Zhou et al. MOLECULAR THERAPY
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
- (2015) L. Zhang et al. CLINICAL CANCER RESEARCH
- T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice
- (2015) Heather VanSeggelen et al. MOLECULAR THERAPY
- Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells
- (2015) Daesik Kim et al. NATURE METHODS
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
- (2014) Shengdar Q Tsai et al. NATURE BIOTECHNOLOGY
- E-CRISP: fast CRISPR target site identification
- (2014) Florian Heigwer et al. NATURE METHODS
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
- (2014) C. Berger et al. Cancer Immunology Research
- Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine
- (2013) Anthony Rongvaux et al. Annual Review of Immunology
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
- (2013) M. Casucci et al. BLOOD
- Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
- (2013) C. R. Y. Cruz et al. BLOOD
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells
- (2013) B. J. Cameron et al. Science Translational Medicine
- Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
- (2012) X. Yao et al. BLOOD
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice
- (2012) Markus Chmielewski et al. GASTROENTEROLOGY
- Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy
- (2012) C Papayannakos et al. GENE THERAPY
- T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term
- (2012) M Chmielewski et al. GENE THERAPY
- Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R null humanized mice
- (2011) E. Billerbeck et al. BLOOD
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
- (2010) Renier Brentjens et al. MOLECULAR THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Eradication of Established B-cell Lymphoma by CD19-specific Murine T Cells is Dependent on Host Lymphopenic Environment and Can be Mediated by CD4+ and CD8+ T Cells
- (2009) Eleanor J. Cheadle et al. JOURNAL OF IMMUNOTHERAPY
- IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes
- (2008) S. Kaneko et al. BLOOD
- Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors
- (2008) M. Bokhoven et al. JOURNAL OF VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started